FDA to Hold Joint Meeting of Anti-Infective Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee to Discuss COVID-19 Treatment Approval Amendment

Summary

The FDA will hold a joint meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss an amendment to the notice regarding the approval of new treatments for COVID-19. The meeting is scheduled to take place on October 17, 2024, and will be available to watch online at https://www.fda.gov/live, with a live stream starting at 10:00 AM ET.